DMAC
DiaMedica Therapeutics Inc.
Price Chart
No historical data available
Latest Quote
$6.35
-0.04 (-0.63%)
Current Price
| Previous Close | $6.39 |
| Open | $6.36 |
| Day High | $6.59 |
| Day Low | $6.22 |
| Volume | 135,123 |
Stock Information
| Shares Outstanding | 53.93M |
| Total Debt | $185K |
| Cash Equivalents | $43.50M |
| Net Income | $-37.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $342.43M |
| EPS (TTM) | $-0.72 |
| Exchange | NCM |
Recent Price History
No history data available. Data will be fetched automatically.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
đ° Latest News
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
Zacks âĸ 2026-08-26T13:55:04Z
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
Motley Fool âĸ 2026-08-18T01:29:44Z
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
Zacks âĸ 2026-08-13T16:00:02Z
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...
GuruFocus.com âĸ 2026-08-11T19:01:13ZDiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby âĸ 2026-08-11T17:26:03Z
DiaMedica Therapeutics Q2 Earnings Call Highlights
MarketBeat âĸ 2026-08-11T13:04:35Z
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
Insider Monkey âĸ 2026-08-03T15:09:16Z
DiaMedica (DMAC) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-06-01T20:17:45Z
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2026-05-10T14:59:26Z
DiaMedica Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T17:42:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $34,397,000 | $26,681,000 | $21,267,000 | $14,001,000 |
| Other Income Expense | $1,659,000 | $2,267,000 | $1,929,000 | $353,000 |
| Other Non Operating Income Expenses | $1,659,000 | $2,267,000 | $1,929,000 | $353,000 |
| Operating Expense | $34,397,000 | $26,681,000 | $21,267,000 | $14,001,000 |
| General And Administrative Expense | $9,783,000 | $7,624,000 | $8,157,000 | $6,162,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Normalized Income | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Net Income From Continuing And Discontinued Operation | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Total Operating Income As Reported | $-34,397,000 | $-26,681,000 | $-21,267,000 | $-14,001,000 |
| Net Income Common Stockholders | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Net Income | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Net Income Including Noncontrolling Interests | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Net Income Continuous Operations | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Pretax Income | $-32,738,000 | $-24,414,000 | $-19,338,000 | $-13,648,000 |
| Operating Income | $-34,397,000 | $-26,681,000 | $-21,267,000 | $-14,001,000 |
| Per Share | ||||
| Diluted EPS | $-0.70 | $-0.60 | $-0.60 | $-0.52 |
| Basic EPS | $-0.70 | $-0.60 | $-0.60 | $-0.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-34,354,000 | $-26,642,000 | $-21,237,000 | $-13,976,000 |
| Reconciled Depreciation | $43,000 | $39,000 | $30,000 | $25,000 |
| EBITDA (Bullshit earnings) | $-34,354,000 | $-26,642,000 | $-21,237,000 | $-13,976,000 |
| EBIT | $-34,397,000 | $-26,681,000 | $-21,267,000 | $-14,001,000 |
| Diluted Average Shares | $46,980,777 | $40,404,681 | $32,566,723 | $26,443,067 |
| Basic Average Shares | $46,980,777 | $40,404,681 | $32,566,723 | $26,443,067 |
| Diluted NI Availto Com Stockholders | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Tax Provision | $28,000 | $30,000 | $43,000 | $28,000 |
| Research And Development | $24,614,000 | $19,057,000 | $13,110,000 | $7,839,000 |
| Selling General And Administration | $9,783,000 | $7,624,000 | $8,157,000 | $6,162,000 |
| Other Gand A | $9,783,000 | $7,624,000 | $8,157,000 | $6,162,000 |
Fetched: 2026-08-28
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Total Assets | $61,371,000 | $46,345,000 | $54,160,000 | $34,395,000 |
| Total Non Current Assets | $742,000 | $1,735,000 | $485,000 | $560,000 |
| Non Current Prepaid Assets | $0 | $1,308,000 | $0 | - |
| Non Current Deferred Assets | $400,000 | $0 | - | - |
| Current Assets | $60,629,000 | $44,610,000 | $53,675,000 | $33,835,000 |
| Other Current Assets | $481,000 | $227,000 | $411,000 | $251,000 |
| Receivables | $258,000 | $236,000 | $369,000 | $82,000 |
| Accrued Interest Receivable | $250,000 | $235,000 | $298,000 | $80,000 |
| Accounts Receivable | $8,000 | $1,000 | $71,000 | $2,000 |
| Cash Cash Equivalents And Short Term Investments | $59,890,000 | $44,147,000 | $52,895,000 | $33,502,000 |
| Cash And Cash Equivalents | $15,647,000 | $3,025,000 | $4,543,000 | $4,728,000 |
| Prepaid Assets | - | - | $411,000 | $251,000 |
| Other Receivables | - | - | - | $2,000 |
| Debt | ||||
| Total Debt | $240,000 | $340,000 | $400,000 | $469,000 |
| Long Term Debt And Capital Lease Obligation | $128,000 | $237,000 | $317,000 | $400,000 |
| Current Debt And Capital Lease Obligation | $112,000 | $103,000 | $83,000 | $69,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,260,000 | $5,627,000 | $3,103,000 | $2,568,000 |
| Total Non Current Liabilities Net Minority Interest | $128,000 | $237,000 | $317,000 | $400,000 |
| Current Liabilities | $5,132,000 | $5,390,000 | $2,786,000 | $2,168,000 |
| Payables And Accrued Expenses | $3,640,000 | $4,227,000 | $1,937,000 | $1,432,000 |
| Payables | $1,475,000 | $940,000 | $926,000 | $734,000 |
| Accounts Payable | $1,475,000 | $940,000 | $926,000 | $734,000 |
| Equity | ||||
| Common Stock Equity | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Total Equity Gross Minority Interest | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Stockholders Equity | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Gains Losses Not Affecting Retained Earnings | $50,000 | $23,000 | $6,000 | $-74,000 |
| Other Equity Adjustments | $50,000 | $23,000 | $6,000 | $-74,000 |
| Retained Earnings | $-172,768,000 | $-140,002,000 | $-115,558,000 | $-96,177,000 |
| Other | ||||
| Ordinary Shares Number | $53,742,370 | $42,818,660 | $37,958,000 | $26,443,067 |
| Share Issued | $53,742,370 | $42,818,660 | $37,958,000 | $26,443,067 |
| Tangible Book Value | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Invested Capital | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Working Capital | $55,497,000 | $39,220,000 | $50,889,000 | $31,667,000 |
| Capital Lease Obligations | $240,000 | $340,000 | $400,000 | $469,000 |
| Total Capitalization | $56,111,000 | $40,718,000 | $51,057,000 | $31,827,000 |
| Additional Paid In Capital | $228,829,000 | $180,697,000 | $166,609,000 | $128,078,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $128,000 | $237,000 | $317,000 | $400,000 |
| Current Capital Lease Obligation | $112,000 | $103,000 | $83,000 | $69,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,380,000 | $1,060,000 | $766,000 | $667,000 |
| Current Accrued Expenses | $2,165,000 | $3,287,000 | $1,011,000 | $698,000 |
| Net PPE | $342,000 | $427,000 | $485,000 | $560,000 |
| Accumulated Depreciation | $-150,000 | $-114,000 | $-100,000 | $-80,000 |
| Gross PPE | $492,000 | $541,000 | $585,000 | $640,000 |
| Leases | $16,000 | $16,000 | $16,000 | $16,000 |
| Machinery Furniture Equipment | $279,000 | $246,000 | $215,000 | $200,000 |
| Buildings And Improvements | $197,000 | $279,000 | $354,000 | $424,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $44,243,000 | $41,122,000 | $48,352,000 | $28,774,000 |
| Treasury Shares Number | - | - | $0 | - |
| Other Properties | - | - | - | - |
Fetched: 2026-08-28
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,102,000 | $-22,101,000 | $-18,752,000 | $-11,592,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-29,062,000 | $-22,076,000 | $-18,728,000 | $-11,511,000 |
| Cash Flow From Continuing Operating Activities | $-29,062,000 | $-22,076,000 | $-18,728,000 | $-11,511,000 |
| Investing Activities | ||||
| Capital Expenditure | $-40,000 | $-25,000 | $-24,000 | $-81,000 |
| Investing Cash Flow | $-2,192,000 | $8,564,000 | $-18,299,000 | $11,538,000 |
| Cash Flow From Continuing Investing Activities | $-2,192,000 | $8,564,000 | $-18,299,000 | $11,538,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $43,282,000 | $11,747,000 | $36,848,000 | $0 |
| Financing Cash Flow | $43,876,000 | $11,994,000 | $36,842,000 | $-6,000 |
| Cash Flow From Continuing Financing Activities | $43,876,000 | $11,994,000 | $36,842,000 | $-6,000 |
| Net Other Financing Charges | $-400,000 | - | - | - |
| Net Common Stock Issuance | $43,282,000 | $11,747,000 | $36,848,000 | $0 |
| Common Stock Issuance | $43,282,000 | $11,747,000 | $36,848,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-10,000 | $-9,000 | $-6,000 | $-6,000 |
| Income Tax Paid Supplemental Data | $28,000 | $26,000 | $33,000 | $27,000 |
| End Cash Position | $15,647,000 | $3,025,000 | $4,543,000 | $4,728,000 |
| Beginning Cash Position | $3,025,000 | $4,543,000 | $4,728,000 | $4,707,000 |
| Changes In Cash | $12,622,000 | $-1,518,000 | $-185,000 | $21,000 |
| Proceeds From Stock Option Exercised | $1,004,000 | $256,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-10,000 | $-9,000 | $-6,000 | $-6,000 |
| Net Long Term Debt Issuance | $-10,000 | $-9,000 | $-6,000 | $-6,000 |
| Long Term Debt Payments | $-10,000 | $-9,000 | $-6,000 | $-6,000 |
| Net Investment Purchase And Sale | $-2,152,000 | $8,589,000 | $-18,275,000 | $11,619,000 |
| Sale Of Investment | $57,126,000 | $59,000,000 | $51,135,000 | $57,303,000 |
| Purchase Of Investment | $-59,278,000 | $-50,411,000 | $-69,410,000 | $-45,684,000 |
| Net PPE Purchase And Sale | $-40,000 | $-25,000 | $-24,000 | $-81,000 |
| Purchase Of PPE | $-40,000 | $-25,000 | $-24,000 | $-81,000 |
| Change In Working Capital | $675,000 | $1,512,000 | $93,000 | $585,000 |
| Change In Payables And Accrued Expense | $-357,000 | $2,503,000 | $540,000 | $591,000 |
| Change In Accrued Expense | $-892,000 | $2,489,000 | $348,000 | $366,000 |
| Change In Payable | $535,000 | $14,000 | $192,000 | $225,000 |
| Change In Account Payable | $535,000 | $14,000 | $192,000 | $225,000 |
| Change In Prepaid Assets | $1,054,000 | $-1,124,000 | $-160,000 | $-54,000 |
| Change In Receivables | $-22,000 | $133,000 | $-287,000 | $48,000 |
| Other Non Cash Items | $82,000 | $75,000 | $70,000 | $64,000 |
| Stock Based Compensation | $3,846,000 | $2,085,000 | $1,683,000 | $1,502,000 |
| Amortization Of Securities | $-942,000 | $-1,343,000 | $-1,223,000 | $-11,000 |
| Depreciation Amortization Depletion | $43,000 | $39,000 | $30,000 | $25,000 |
| Depreciation And Amortization | $43,000 | $39,000 | $30,000 | $25,000 |
| Depreciation | $43,000 | $39,000 | $30,000 | $25,000 |
| Net Income From Continuing Operations | $-32,766,000 | $-24,444,000 | $-19,381,000 | $-13,676,000 |
| Sale Of PPE | - | - | - | $0 |
Fetched: 2026-08-28